Literature DB >> 21318319

Noninvasive monitoring of tumor growth in a rat glioma model: comparison between neurological assessment and animal imaging.

Ting-Chung Wang1, Ing-Tsung Hsiao, Yu-Kai Cheng, Shiaw-Pyng Wey, Tzu-Chen Yen, Kun-Ju Lin.   

Abstract

Malignant gliomas are the most common primary tumors that arise from glial cells and are characterized by extensive invasiveness and rapid progression. Limitation of the current therapeutic regimen for malignant glioma warrants the development of new therapies strategies. In order to investigate new methods of therapy, establishment of a reliable animal model is essential both in studying the tumor biology and trialing a new therapeutic strategy. Noninvasive monitoring of tumor growth in living animals may be important for new therapeutic strategy development. The development of animal imaging techniques has improved our ability to investigate animal models of malignant gliomas. In this study, both neurological examination and positron emission tomography (PET) with (18)F-FDG were used to monitor tumor growth in a rat glioma model. Visual limb placing, tactile limb placing, and beam walking tests were used to assess neurological deficits. Neurobehavioral alterations were correlated with PET findings and histopathological data. Seven days after surgery, the tumor was clearly visible on PET images. Results of behavioral tests correlated well with imaging data and histopathological findings. PET is feasible to detect experimental rat gliomas in their early stage of development. In contrast, standard neurological assessment is useful for monitoring tumor growth during the course of the disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21318319     DOI: 10.1007/s11060-011-0538-0

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  22 in total

1.  Neocortical localization of tactile/proprioceptive limb placing reactions in the rat.

Authors:  M De Ryck; J Van Reempts; H Duytschaever; B Van Deuren; G Clincke
Journal:  Brain Res       Date:  1992-02-21       Impact factor: 3.252

2.  Quantitative aspects of normal locomotion in rats.

Authors:  R E Hruska; S Kennedy; E K Silbergeld
Journal:  Life Sci       Date:  1979-07-09       Impact factor: 5.037

3.  Long term reshaping of language, sensory, and motor maps after glioma resection: a new parameter to integrate in the surgical strategy.

Authors:  H Duffau; D Denvil; L Capelle
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

4.  Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis.

Authors:  Steven M. Larson; Yusuf Erdi; Timothy Akhurst; Madhu Mazumdar; Homer A. Macapinlac; Ronald D. Finn; Cecille Casilla; Melissa Fazzari; Neil Srivastava; Henry W.D. Yeung; John L. Humm; Jose Guillem; Robert Downey; Martin Karpeh; Alfred E. Cohen; Robert Ginsberg
Journal:  Clin Positron Imaging       Date:  1999-05

5.  PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization.

Authors:  Roland H Goldbrunner; Martin Bendszus; Jeanette Wood; Michael Kiderlen; Masato Sasaki; Jörg-Christian Tonn
Journal:  Neurosurgery       Date:  2004-08       Impact factor: 4.654

6.  Work in progress: [18F] fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain.

Authors:  N J Patronas; G Di Chiro; R A Brooks; R L DeLaPaz; P L Kornblith; B H Smith; H V Rizzoli; R M Kessler; R G Manning; M Channing; A P Wolf; C M O'Connor
Journal:  Radiology       Date:  1982-09       Impact factor: 11.105

7.  Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy.

Authors:  Eduard B Dinca; Jann N Sarkaria; Mark A Schroeder; Brett L Carlson; Ramona Voicu; Nalin Gupta; Mitchel S Berger; C David James
Journal:  J Neurosurg       Date:  2007-09       Impact factor: 5.115

8.  Forelimb use after focal cerebral ischemia in rats treated with an alpha 2-adrenoceptor antagonist.

Authors:  Heli Karhunen; Tiina Virtanen; Timothy Schallert; Juhani Sivenius; Jukka Jolkkonen
Journal:  Pharmacol Biochem Behav       Date:  2003-02       Impact factor: 3.533

9.  FDG-PET imaging for the evaluation of antiglioma agents in a rat model.

Authors:  Sarah Assadian; Antonio Aliaga; Rolando F Del Maestro; Alan C Evans; Barry J Bedell
Journal:  Neuro Oncol       Date:  2008-04-22       Impact factor: 12.300

10.  Photochemical stroke model: flunarizine prevents sensorimotor deficits after neocortical infarcts in rats.

Authors:  M De Ryck; J Van Reempts; M Borgers; A Wauquier; P A Janssen
Journal:  Stroke       Date:  1989-10       Impact factor: 7.914

View more
  4 in total

1.  CT-based handling and analysis of preclinical multimodality imaging data of bone metastases.

Authors:  Thomas J A Snoeks; Martin Baiker; Eric L Kaijzel; Boudewijn P F Lelieveldt; Clemens W G M Löwik
Journal:  Bonekey Rep       Date:  2012-05-09

2.  Dynamic 11C-methionine PET analysis has an additional value for differentiating malignant tumors from granulomas: an experimental study using small animal PET.

Authors:  Songji Zhao; Yuji Kuge; Min Yi; Yan Zhao; Toshiyuki Hatano; Keiichi Magota; Ken-ichi Nishijima; Masashi Kohanawa; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07-06       Impact factor: 9.236

3.  Modulation of p75 neurotrophin receptor under hypoxic conditions induces migration and invasion of C6 glioma cells.

Authors:  Ting-Chung Wang; Sheng-Jie Luo; Chun-Liang Lin; Pey-Jium Chang; Miao-Fen Chen
Journal:  Clin Exp Metastasis       Date:  2014-12-20       Impact factor: 5.150

4.  Characterization of highly proliferative secondary tumor clusters along host blood vessels in malignant glioma.

Authors:  Ting-Chung Wang; Chun-Yu Cheng; Wei-Hsun Yang; Wen-Cheng Chen; Pey-Jium Chang
Journal:  Mol Med Rep       Date:  2015-08-18       Impact factor: 2.952

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.